CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Good Start Genetics®, Inc., an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability, today announced that new data further supporting their robust platform validation and the clinical value of the GoodStart SelectTM carrier screening test will be presented during two poster sessions at the 2013 American Society for Reproductive Medicine Annual Meeting taking place October 12 – 17 in Boston.
The schedule for presentations by Good Start Genetics is as follows:
Date & Time: Tuesday, October 15, 2013 from 7:00 – 8:45 a.m.
Title: A RIGOROUS PROCESS FOR SELECTING AN OPTIMAL MUTATION SET FOR POPULATION-BASED CARRIER SCREENING
Program Number: P018
Session ID: P-149
Date & Time: Thursday, October 17, 2013 from 7:00 – 8:45 a.m.
Title: CARRIER SCREENING OF 8,500 IVF PATIENTS UTILIZING NEXT GENERATION DNA SEQUENCING DETECTS COMMON, RARE AND OTHERWISE UNDETECTABLE MUTATIONS ACROSS SOCIETY-RECOMMENDED DISEASES
Program Number: P048
Session ID: P-1151
About GoodStart Select™
GoodStart Select is Good Start Genetics’ menu of carrier screening tests that, for diseases such as cystic fibrosis, detects many more disease-causing mutations than any other routine carrier screening test, regardless of patient ethnicity. After years of development and rigorous validation, Good Start Genetics has harnessed the power of its sophisticated technologies, including next-generation DNA sequencing (NGS), to provide highly accurate and actionable tests resulting in higher mutation detection rates and fewer missed carriers. Good Start offers genetic screening tests for all disorders recommended by the American Congress of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG), and leading Jewish advocacy groups.
To support the company’s gold standard genetic screening capabilities, Good Start has a dedicated team of customer care specialists, board certified medical geneticists and genetic counselors who provide step-by-step support, from test selection through results, analysis and reporting. For these reasons, reproductive health specialists and their patients can have the highest degree of confidence in their genetic carrier screening results.
Good Start Genetics is an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability combined with other technologies to deliver best-in-class tests for routine genetic screening. Through its GoodStart Select™ offering, the company provides the most comprehensive and clinically actionable set of tests for known and novel mutations that cause inherited diseases. Good Start’s NGS capabilities can be applied to multiple disease areas, including pre-conception carrier screening in the in-vitro fertilization setting. For more information, please visit www.goodstartgenetics.com.